Linaclotide 72 micrograms — Competitive Intelligence Brief

Linaclotide 72 micrograms (Linaclotide 72 micrograms) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Guanylate cyclase-C agonist. Area: Gastroenterology.

marketed Guanylate cyclase-C agonist GC-C (guanylate cyclase-C receptor) Gastroenterology Small molecule

Target snapshot

Linaclotide 72 micrograms (Linaclotide 72 micrograms) — Md Mehedi Shahriar. Linaclotide is a guanylate cyclase-C (GC-C) agonist that increases intracellular cyclic GMP in intestinal epithelial cells, promoting fluid secretion and accelerating intestinal transit.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Linaclotide 72 micrograms TARGET	Linaclotide 72 micrograms	Md Mehedi Shahriar	marketed	Guanylate cyclase-C agonist	GC-C (guanylate cyclase-C receptor)
Trulance	PLECANATIDE	Salix	marketed	Guanylate Cyclase-C Agonist [EPC]	Tumor necrosis factor	2017-01-01
Linzess	LINACLOTIDE	AbbVie	marketed	Guanylate Cyclase-C Agonist [EPC]	Heat-stable enterotoxin receptor	2012-01-01
XOI	XOI	Ironwood Pharmaceuticals, Inc.	marketed	Guanylate cyclase-C agonist	GC-C (guanylate cyclase-C)
AJG555	AJG555	EA Pharma Co., Ltd.	phase 3	Guanylate cyclase-C agonist	GC-C (guanylate cyclase-C)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Guanylate cyclase-C agonist class)

1. EA Pharma Co., Ltd. · 1 drug in this class
2. Ironwood Pharmaceuticals, Inc. · 1 drug in this class
3. Md Mehedi Shahriar · 1 drug in this class